NCT06681259 Clinical Specialty Queue For Gestational Trophoblastic Neoplasia
| NCT ID | NCT06681259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Women's Hospital School Of Medicine Zhejiang University |
| Condition | Gestational Trophoblastic Neoplasia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-11-04 |
| Primary Completion | 2029-11-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-11-04 with a primary completion date of 2029-11-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to establish a bidirectional cohort study of GTN specific diseases, including 1020 retrospective cases Queue and 1000 prospective cohorts. Based on the clinical collaboration system for gynecological tumors in multiple tertiary hospitals across the country, establish unified criteria for case inclusion and exclusion, and establish a multi center clinical queue for GTN; Collect baseline information of GTN patients, such as age, reproductive history, environmental and social information, genetic related information, physical examination, physicochemical, imaging, and pathological information; Collect biological specimens such as blood/tissue from patients; Collect information related to the diagnosis, treatment plan, human chorionic gonadotropin (hCG) levels, and toxic side effects of patients during the diagnosis and treatment period; After the end of treatment, follow-up blood hCG levels, imaging, fertility status, as well as recurrence and metastasis status, are conducted to track prognosis, thus building a clinical diagnosis and treatment information database, forming a standardized follow-up system for GTN, identifying high-risk factors for GTN chemotherapy resistance, constructing a precise evaluation model for GTN resistance, and providing high-level evidence-based medicine for effectively improving the initial treatment efficacy of GTN.
Eligibility Criteria
Inclusion Criteria: * ① Age ≥ 18 years old; ② Patients clinically diagnosed with GTN (including invasive cases) Molar pregnancy, choriocarcinoma, PSTT, ETT); ③ Complete informed consent for enrollment. Exclusion Criteria: * ① Having mental illness or cognitive impairment, unable to cooperate in completing the investigation with Patients with concurrent malignant tumors; ③ Participants with severe missing follow-up data.
Frequently Asked Questions
Who can join the NCT06681259 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Gestational Trophoblastic Neoplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06681259 currently recruiting?
Yes, NCT06681259 is actively recruiting participants. Visit ClinicalTrials.gov or contact Women's Hospital School Of Medicine Zhejiang University to inquire about joining.
Where is the NCT06681259 trial being conducted?
This trial is being conducted at Zhengjiang, China.
Who is sponsoring the NCT06681259 clinical trial?
NCT06681259 is sponsored by Women's Hospital School Of Medicine Zhejiang University. The trial plans to enroll 1,000 participants.